volume 30, issue 2, P439-459 2012
DOI: 10.3233/jad-2012-111862
View full text
Has erratum
|
Sign up to set email alerts
|
Share

Abstract: The present study shows that chronic administration of the cannabinoid receptor type 1 (CB1) receptor agonist arachidonyl-2-chloroethylamide (ACEA) at pre-symptomatic or at early symptomatic stages, at a non-amnesic dose, reduces the cognitive impairment observed in double AβPP(swe)/PS1(1dE9) transgenic mice from 6 months of age onwards. ACEA has no effect on amyloid-β (Aβ) production, aggregation, or clearance. However, ACEA reduces the cytotoxic effect of Aβ42 oligomers in primary cultures of cortical neuron…

Expand abstract
Editorial notices

Search citation statements

Order By: Relevance

Citation Types

4
45
0
4

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals